Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.46 – $0.584
Volume97,807
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.16M
Price / earnings
—
Price / book
0.19×
Price / sales
—
EV / sales
—
EV / EBITDA
0.32×
Profitability
Earnings per share
-$13.24
Return on assets
-192.71%
Return on equity
-463.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.08×
Quick ratio
2.08×
Cash ratio
1.89×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$25.34M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for APVO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.75M
$2.91M
$2.46M
$3.57M
$2.9M
$2.85M
$2.5M
$2.11M
Research and development
$3.7M
$3.92M
$3.54M
$4.04M
$3.33M
$3.63M
$3.88M
$3.1M
Total operating expenses
$6.44M
$6.84M
$6M
$7.61M
$6.23M
$6.48M
$6.38M
$5.21M
Operating income
-$6.44M
-$6.84M
-$6M
-$7.61M
-$6.23M
-$6.48M
-$6.38M
-$5.21M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.36M
-$6.7M
-$5.81M
-$7.55M
-$6.2M
-$6.41M
-$6.31M
-$5.1M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.36M
-$6.7M
-$5.81M
-$7.55M
-$6.2M
-$6.41M
-$6.31M
-$5.1M
Net income attributable to common shareholders
-$6.36M
-$6.7M
-$5.9M
-$9.03M
-$6.2M
-$6.41M
-$6.31M
-$5.1M
EBITDA
-$6.41M
-$6.8M
-$5.92M
-$7.56M
-$6.18M
-$6.42M
-$6.31M
-$5.13M
Basic earnings per share
-$5.31
-$6.41
-$5.94
-$40.14
-$151.29
-$1,581.81
-$3,219.86
-$6,441.48
Diluted earnings per share
-$5.31
-$6.41
-$5.94
-$40.14
-$151.29
-$1,581.81
-$3,219.86
-$6,441.48
Recent news
Company coverage with links to the original publishers.
Aptevo Therapeutics reported a net loss of $8.40 per share in Q2 2025, significantly better than analyst estimates. The company's lead bispecific antibody, mipletamig, showed promising 85% remission rates in acute myeloid leukemia trials, and raised $15.9 million in equity to extend its cash runway.
Bloom Energy shares jumped 12.1% after announcing a strategic partnership with CoreWeave to deploy its fuel cells for on-site power generation at a data center. Several other stocks also saw significant pre-market movements, both positive and negative.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Groupon (GRPN), Aptevo Therapeutics (APVO), NewJersey Resources (NJR), American Water Works (AWK) and Frontdoor (FTDR).
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.